A large-scale trial enrolling sepsis patients across diverse geographical regions of India is needed to confirm the prognostic accuracy of the IL-6, PT-INR, and HDL biomarker panel and to establish the generalizability of the proposed risk prediction model. The gene discussed is IL6; the disease is Sepsis.